Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call

SAN DIEGO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) (www.apricusbio.com) announced today that it will hold a conference call to discuss its first quarter 2013 financial results and recent corporate highlights on Friday, May 10, 2013 at 9:00 a.m. ET. The Company expects to file its Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on Friday, May 10, 2013.

The call can be accessed in the U.S. by dialing 877-407-9210 and outside of the U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus Bio Conference Call. The conference call will also be webcast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=170957. The teleconference replay will be available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay Passcode 413843 is required for playback. The webcast replay will be available for three months.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros(R), for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories, and Femprox(R), a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one approximately 400-patient Phase III study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com. You can also receive information at http://twitter.com/apricusbio.

Go here to see the original:

Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call